<DOC>
	<DOCNO>NCT00811369</DOCNO>
	<brief_summary>The purpose study evaluate whether combination fulvestrant ZACTIMA , versus fulvestrant plus placebo , result significant decrease bone marker , urinary N-Telopeptide ( NTx ) postmenopausal woman bone , bone predominant , hormone receptor-positive metastatic breast cancer . A significant decrease define &gt; 30 % reduction urinary NTx level baseline .</brief_summary>
	<brief_title>Trial Evaluate Therapeutic Benefit Fulvestrant Combination With ZACTIMA Postmenopausal Women With Bone Predominant , Hormone Receptor Positive Metastatic Breast Cancer</brief_title>
	<detailed_description>Tumor angiogenesis associate invasiveness metastatic potential various cancer . Vascular endothelial growth factor ( VEGF ) , potent specific angiogenic factor , regulate normal pathologic angiogenesis . The increased expression VEGF correlate metastasis , recurrence poor prognosis many cancer . It show VEGF involved osteolysis woman bone metastasis . ZACTIMA agent target VEGF . ZACTIMA new agent novel method action - VEGF inhibitor , epidermal growth factor ( EGFR ) inhibitor , tyrosine kinase inhibitor , well potential RET kinase activity inhibitor . In summary , woman bone , bone predominant , metastatic breast cancer ideal group study anti-angiogenic therapy angiogenesis could major factor tumor progression anti-angiogenic treatment agent like ZACTIMA could effective .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>1 . Postmenopausal woman , define woman fulfil one follow criterion : Age great equal 60 year Age great equal 45 year amenorrhea 12 month intact uterus Folliclestimulating hormone ( FSH ) level postmenopausal range Having undergone bilateral oophorectomy 2 . Metastatic breast cancer either radiologically confirm bone predominant metastases bone consider amenable curative treatment . 3 . Evidence hormone sensitivity either ER+ and/or PgR+ , per institutional standard , primary tumor . 4 . Patients must fulfill one follow RECIST criterion : Bone lesion , lytic , sclerotic mixed ( lytic + sclerotic ) , absence measurable disease define RECIST criterion Bone lesion , lytic , sclerotic mixed ( lytic + sclerotic ) , presence measurable disease define RECIST criterion . 5 . Patients must fulfill one follow resistance endocrine therapy criterion : Disease progression tamoxifen aromatase inhibitor first second line therapy metastatic disease Development metastatic disease treatment tamoxifen aromatase inhibitor adjuvant set Disease progression discontinuation prior adjuvant endocrine therapy . 1 . Previous treatment fulvestrant ZACTIMA . 2 . History hypersensitivity active inactive excipients fulvestrant and/or ZACTIMA . 3 . Has receive great one line systemic chemotherapy metastatic breast cancer . 4 . Has receive chemotherapy within past 14 day ( + 2 day ) . 5 . Has receive radiation therapy within past 14 day ( + 2 day ) . 6 . Has undergone major surgery within past 21 day major surgery perform &gt; 21 day prior screen wound remain unhealed . 7 . Has receive LHRH agonist within past 4 month . 8 . Prior treatment VEGF inhibitor ( prior use AVASTIN permit ) . 9 . Current previously active systemic malignancy within 3 year prior randomization ( breast cancer , adequately treat insitu carcinoma cervix , uteri , basal squamous cell carcinoma skin ) . 10 . Presence lifethreatening metastatic visceral disease , define extensive hepatic involvement , degree brain leptomeningeal involvement ( past present ) , symptomatic pulmonary lymphangetic spread . Patients discrete pulmonary parenchymal metastasis eligible , provided respiratory function compromise result disease . 11 . ECOG performance status &gt; 2 . 12 . Currently receive ( unwilling discontinue ) hormone replacement therapy . 13 . Laboratory result sustain : Platelets &lt; 100 x 109 /L International normalize ratio ( INR ) &gt; 1.6 Total bilirubin &gt; 1.5 time normal ALT AST &gt; 2.5 time normal range demonstrable liver metastasis &gt; 5 time normal range presence liver metastasis . No three retests within screen period allowable . 14 . Potassium level outside normal range , despite supplementation ; serum calcium ( ionize adjust albumin ) , magnesium low limit normal range despite supplementation creatinine clearance &lt; 30mL/min . 15 . History : Bleeding diathesis ( i.e . disseminate intravascular coagulation [ DIC ] , clot factor deficiency ) Longterm anticoagulant therapy ( antiplatelet therapy ) . 16 . Any severe concomitant condition make undesirable patient participate study would jeopardize compliance protocol , e.g . severe renal hepatic impairment currently unstable uncompensated respiratory cardiac condition , ongoing active infection , untreated primary hyperparathyroidism , psychiatric illness would limit compliance study requirement . 17 . Anticipated life expectancy less six month . 18 . Nonapproved/experimental drug treatment within previous 4 week randomization . 19 . Significant cardiovascular event ( e.g. , myocardial infarction , superior vena cava syndrome ) , New York Heart Association ( NYHA ) classification heart disease ( Appendix II ) &gt; Class II within 3 month study entry , presence cardiac disease opinion investigator increase risk ventricular arrhythmia . 20 . History arrhythmia ( multifocal premature ventricular contraction ( PVCs ) , bigeminy , trigeminy , ventricular tachycardia , uncontrolled atrial fibrillation ) symptomatic require treatment ( NCI CTCAE Grade 3 4 ) asymptomatic sustain ventricular tachycardia . Atrial fibrillation , control medication , exclude . 21 . Congenital long QT syndrome 1st degree relative unexplained sudden death 40 year age . 22 . QT prolongation medication require discontinuation medication . 23 . Presence leave bundle branch block ( LBBB ) . 24 . QTc Bazett 's correction measurable &gt; 480msec screen ECG . ( Note : If patient QTc &gt; 480msec screen ECG , screen ECG may repeat twice ( least 24 hour apart ) . The average QTc three screen ECGs must &lt; 480msec order patient eligible study ) . Patients receive drug risk QTc prolongation ( see Appendix III , Table 2 ) exclude QTc &gt; 460msec . 25 . Hypertension control medical therapy ( systolic blood pressure &gt; 160 millimeter mercury ( mmHg ) diastolic blood pressure &gt; 100mmHg ) . 26 . Concomitant medication potent inducer ( rifampicin , rifabutin , phenytoin , carbamazepine , phenobarbital St. John 's Wort ) CYP3A4 function . 27 . Not accessible treatment follow . 28 . Failure provide inform consent .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Bone Metastases</keyword>
	<keyword>Telopeptide</keyword>
	<keyword>Zactima</keyword>
	<keyword>Fulvestrant</keyword>
</DOC>